Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131403) titled 'Efficacy and safety of hepatic arterial infusion chemotherapy combined with apatinib and adebrelimab for high-risk BCLC stage C hepatocellular carcinoma: A single-arm, multicenter, phase II study' on Sept. 1.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: Sun Yat-Sen University Cancer Center
Condition:
Hepatocellular carcinoma
Recruitment Status: Recruiting
Phase: 2
Date of First Enrollment: 2025-05-14
Target Sample Size: Experimental group:40;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=292773
Disclaimer: Curated by...